{"id":"W2947217282","doi":"10.1200/jco.2019.37.15_suppl.1002","title":"Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Capecitabine; Medicine; Lapatinib; Internal medicine; Neratinib; Metastatic breast cancer; Gastroenterology; Clinical endpoint; Randomized controlled trial; Breast cancer; Oncology; Cancer; Trastuzumab; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002624286,0.001089308,0.00178533,0.0003236999,0.0002944225,0.0009029129,0.0006550536,0.0009819785,0.004491156],"category_scores_gemma":[0.00187877,0.0004514105,0.001951308,0.0003510952,0.0006843435,0.0009171557,0.0003871538,0.00260245,0.0005604802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001162541,"about_ca_system_score_gemma":0.001198463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001167704,"about_ca_topic_score_gemma":0.004883732,"domain_scores_codex":[0.9993037,0.0004334927,0.00004949393,0.00008972781,0.0000408733,0.00008280007],"domain_scores_gemma":[0.9989426,0.0003330948,0.0002712345,0.0000550182,0.00003821772,0.0003598283],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9689883,0.005453678,0.00144345,0.0004413405,0.001201933,0.00003441731,0.00004620331,0.0005381446,0.001722641,0.00007607155,0.0008218795,0.01923204],"study_design_scores_gemma":[0.8785201,0.1124437,0.005609604,0.00005791873,0.0009366063,0.0000758548,0.00003414583,0.0007279155,0.0003993775,0.0001933438,0.0009849279,0.00001657122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899889,0.005314832,0.0002715625,0.0008827932,0.0003472675,0.001130147,0.0005910252,0.00004032802,0.001433021],"genre_scores_gemma":[0.9932002,0.002095505,0.0005747101,0.0008059522,0.0002217982,0.00109194,0.0006506984,0.000009575713,0.001349679],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004491156,"threshold_uncertainty_score":0.01502442,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05348833309670203,"score_gpt":0.4172062872084293,"score_spread":0.3637179541117273,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}